Core Insights - The article discusses the valuation disparity of Celcuity (NASDAQ: CELC) as it progresses through a phase 3 clinical trial for its cancer platform [1] Group 1: Company Overview - Celcuity is currently deep into enrollment for a phase 3 trial, indicating significant progress in its developmental cancer platform [1] Group 2: Analyst Background - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing a commitment to educating investors on the science behind these businesses [1]

Core Insights - The article discusses the valuation disparity of Celcuity (NASDAQ: CELC) as it progresses through a phase 3 clinical trial for its cancer platform [1] Group 1: Company Overview - Celcuity is currently deep into enrollment for a phase 3 trial, indicating significant progress in its developmental cancer platform [1] Group 2: Analyst Background - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing a commitment to educating investors on the science behind these businesses [1]